

## CORRESPONDENCE

OPEN

# Reply: Is nesting addiction medicine and hepatology care in the outpatient setting worthwhile? A retrospective case series at a single tertiary center

We congratulate Gupta and colleagues for their study evaluating the impact of an outpatient integrated model incorporating addiction medicine and hepatology care for patients with alcohol use disorder (AUD). Their results add to the growing evidence that involvement of hepatology care for patients with AUD may improve alcohol therapy engagement.<sup>[1]</sup> These findings are particularly important given the fact that most patients with AUD do not receive therapy targeting their alcohol use,<sup>[2]</sup> which is the best-studied strategy to prevent the development and progression of alcohol-associated liver disease.<sup>[3]</sup> As these integrated models become more established, it will also be important to evaluate the long-term impact of integrated models on liver-related outcomes as well, including progression to cirrhosis, frequency of hepatic decompensation events, transplant eligibility, posttransplant relapse rates and outcomes, and liver-related mortality. Implementing and expanding access to these care models will require a systems-level approach, but the growing body of literature to support an integrated, multidisciplinary approach to AUD and alcohol-associated liver disease care emphasizes the utility.

**FUNDING INFORMATION**

None.

**CONFLICTS OF INTEREST**

The authors have no conflicts to report.

Rachael Mahle<sup>1,2</sup>  
Paige McLean Diaz<sup>1,2</sup>

Chantelle Marshall<sup>1,2</sup>  
Russell P. Goodman<sup>1,2</sup>  
Esperance Schaefer<sup>1,2</sup>  
Jay Luther<sup>1,2</sup>

<sup>1</sup>MGH Alcohol Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

<sup>2</sup>Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

**Correspondence**

Jay Luther, Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.  
Email: [Jluther1@mgh.harvard.edu](mailto:Jluther1@mgh.harvard.edu)

**REFERENCES**

1. Shroff H, Gallagher H. Multidisciplinary care of alcohol-related liver disease and alcohol use disorder: A narrative review for hepatology and addiction clinicians. *Clin Ther.* 2023;45:1177–88.
2. Han B, Jones CM, Einstein EB, Powell PA, Compton WM. Use of medications for alcohol use disorder in the US: Results from the 2019 national survey on drug use and health. *JAMA Psychiatry.* 2021;78:922–4.
3. Vannier AGL, Shay JES, Fomin V, Patel SJ, Schaefer E, Goodman RP, et al. Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder. *JAMA Netw Open.* 2022;5:e2213014.

**Abbreviation:** AUD, alcohol use disorder.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.